Arcus Biosciences, Inc.

NYSE:RCUS

16.46 (USD) • At close November 7, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q1
Revenue 4839145313229250.34533.58126.75918.005354.4999.4619.4619.4619.48764.531.751.759.751.751.751.751.5624.2911.251.251.250.16300
Cost of Revenue 02353443.4293.6093.5293.4332.47371.25468.77166.38748.71251.80135.69323.14220.68617.24124.99915.55411.43612.85913.69911.65212.14621.4357.8345.804
Gross Profit 483714226292521-3.08429.97223.2314.572352.026-61.793-59.31-56.926-39.22512.729-33.943-21.392-10.936-15.491-23.249-13.804-9.874-8.568-12.449-10.402-10.896-21.272-7.834-5.804
Gross Profit Ratio 10.9490.9790.8390.9060.8620.84-8.9390.8930.8680.8090.993-6.531-6.269-6.017-4.1350.197-19.396-12.224-1.122-8.852-13.285-7.888-6.321-1.997-9.959-8.322-8.717-130.50300
Reseach & Development Expenses 123115109938284818076.68469.90561.21149.93671.25468.77166.38748.71251.80135.69323.14220.68617.24124.99915.55411.43612.85913.69911.65212.14621.4357.8345.804
General & Administrative Expenses 303032293028302826.29425.83623.97423.29616.34316.82615.82112.78711.17711.4327.0086.5917.7585.9114.9693.613.5773.452.9292.4481.8621.831.496
Selling & Marketing Expenses 0-200000000000000000000000000000
SG&A 302832293028302826.29425.83623.97423.29616.34316.82615.82112.78711.17711.4327.0086.5917.7585.9114.9693.613.5773.452.9292.4481.8621.831.496
Other Expenses 00200000000000000000000000000000
Operating Expenses 153143141122112112111108102.97895.74185.18573.23287.59785.59782.20861.49962.97847.12530.1527.27724.99930.9120.52315.04616.43617.14914.58114.59423.2979.6647.3
Operating Income -105-106-16-91-80-83-86-74-69.397-68.982-67.18281.267-78.136-76.136-72.747-52.0121.552-45.375-28.4-17.527-23.249-29.16-18.773-13.484-12.145-15.899-13.331-13.344-23.134-9.664-7.3
Operating Income Ratio -2.188-2.718-0.11-2.935-2.5-2.862-3.44-214.493-2.067-2.578-3.7310.793-8.259-8.047-7.689-5.4820.024-25.929-16.229-1.798-13.285-16.663-10.727-8.633-2.83-12.719-10.665-10.675-141.92600
Total Other Income Expenses Net 1313-2011119874.4782.350.191-0.260.1610.1660.1540.1590.270.3010.6470.929-0.357-0.412-0.431-0.3231.3332.3660.3770.1340.0120.1140.1
Income Before Tax -92-93-4-80-69-74-78-67-64.919-66.632-66.989281.183-77.975-75.97-72.593-51.8531.822-45.074-27.753-16.598-22.352-28.09-17.67-12.295-10.812-13.533-12.954-13.21-23.122-9.55-7.2
Income Before Tax Ratio -1.917-2.385-0.028-2.581-2.156-2.552-3.12-194.203-1.933-2.49-3.7210.793-8.242-8.03-7.673-5.4660.028-25.757-15.859-1.702-12.773-16.051-10.097-7.871-2.52-10.826-10.363-10.568-141.85300
Income Tax Expense 0011212-0.004-4.478-2.351.0041.815-0.1-0.10.438-1.82-0.258-0.131-0.482-0.856-1.254-1.482-1.534-2.4590000000
Net Income -92-93-4-81-71-75-80-66.996-60.441-64.282-67.993279.368-77.975-75.97-72.593-51.8531.822-45.074-27.753-16.598-22.352-28.09-17.67-12.295-10.812-13.533-12.954-13.21-23.122-9.55-7.2
Net Income Ratio -1.917-2.385-0.028-2.613-2.219-2.586-3.2-194.191-1.8-2.402-3.7760.788-8.242-8.03-7.673-5.4660.028-25.757-15.859-1.702-12.773-16.051-10.097-7.871-2.52-10.826-10.363-10.568-141.85300
EPS -1.01-1.02-0.046-1.08-0.95-1.02-1.1-0.92-0.84-0.9-0.963.97-1.11-1.09-1.08-0.820.03-0.93-0.63-0.38-0.51-0.64-0.41-0.28-0.25-0.32-1.37-0.54-0.94-0.39-0.29
EPS Diluted -1.01-1.02-0.046-1.08-0.95-1.02-1.1-0.92-0.84-0.9-0.963.71-1.11-1.09-1.08-0.820.03-0.93-0.63-0.38-0.51-0.64-0.41-0.28-0.25-0.32-1.37-0.54-0.94-0.39-0.29
EBITDA -105-10420-77-68-74-77-66-62.824-64.616-65.141281.443-76.589-74.737-71.409-52.0122.294-44.719-28.04-17.527-22.363-28.277-17.82-13.484-11.171-14.984-12.503-12.578-22.402-9.036-6.814
EBITDA Ratio -2.188-2.6670.138-2.484-2.125-2.552-3.08-191.304-1.871-2.415-3.6180.794-8.095-7.899-7.548-5.4820.036-25.554-16.023-1.798-12.779-16.158-10.183-8.633-2.603-11.987-10.002-10.062-137.43600